ReviewPathologie (Heidelberg, Germany)2025
[Exanthematic drug eruption].
Review in Pathologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adverse Dermatological Reaction to Mycophenolate Mofetil in a Patient with Systemic Lupus Erythematosus: A Case Report.The American journal of case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBesides reactions of the IgE-mediated immediate type, medicamentous therapies can cause a variety of different mucocutaneous adverse events. Exanthematous manifestations require a fast and certain diagnosis due to their extent, sometimes rapid progression, and mucous membrane or organ involvement.
objectivesThe spectrum of non-IgE-mediated exanthematic drug reactions is covered. MATERIAL AND
methodsThe most relevant reactions are portrayed clinically and histopathologically.
resultsDisplayed are classical maculo-papular drug eruption, lichenoid drug reaction, acute generalized exanthematic pustulosis (AGEP), severe potentially life-threatening drug reactions such as Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) as well as generalized bullous fixed drug eruption (GBFDE), drug reaction with eosinophilia and systemic symptoms (DRESS), and some others.
conclusionsCutaneous drug-related side effects cover a broad spectrum. Important for the correct treatment is a reliable diagnosis. In the case of severe, life-threatening drug reactions, however, permanent discontinuation of the drug is essential.
Indexed as
Identifiers
39964515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.